(VIANEWS) – The NYSE opens in less than hour and Baxter International‘s pre-market value is already 7.74% down.
Baxter International’s last close was $42.74, 14.88% below its 52-week high of $50.21.
The last session, NYSE ended with Baxter International (BAX) jumping 0.12% to $42.74. NYSE rose 0.31% to $18,312.67, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session.
About Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Earnings Per Share
As for profitability, Baxter International has a trailing twelve months EPS of $-0.15.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.96%.
Sales Growth
Baxter International’s sales growth is negative 1.4% for the current quarter and 1.7% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Feb 29, 2024, the estimated forward annual dividend rate is 1.16 and the estimated forward annual dividend yield is 2.65%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 24.5% and 21.8%, respectively.
Yearly Top and Bottom Value
Baxter International’s stock is valued at $42.74 at 10:07 EST, way below its 52-week high of $50.21 and way higher than its 52-week low of $31.01.
More news about Baxter International (BAX).
